We report on sessions on the dapagliflozin effect on cardiovascular events; angiotensin receptor-neprilysin inhibition for acute decompensated heart failure; rivaroxaban's effect on thromboembolic events with heart failure, sinus rhythm, and coronary disease; ... ...

请注册登录后继续浏览